{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:41:06Z","timestamp":1793054466674,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Precision medicine in myelofibrosis (MF) has moved beyond confirmation of a driver mutation toward an integrated interpretation of marrow morphology, molecular profile, cytogenetics, clinical phenotype, symptom burden, and transplant fitness. Myelofibrosis is biologically heterogeneous across both primary MF and secondary MF arising after polycythemia vera or essential thrombocythemia, with clinically relevant differences in disease origin, driver distribution, prognostic model validation, phenotype, and outcome. Several prognostic tools and much of the strongest molecular-risk evidence remain best validated in primary MF cohorts; therefore, PMF-derived molecular signals should be applied cautiously to secondary MF, where MYSEC-PM and disease-origin-specific interpretation are more appropriate. Current precision care is actionable now in diagnosis, integrated risk assessment, phenotype-adapted JAK inhibitor selection, structured symptom assessment, and transplant timing. Ruxolitinib remains the anchor first-line option for symptomatic proliferative disease; fedratinib provides an alternative or post-ruxolitinib option in selected patients with preserved platelet reserve; pacritinib is particularly relevant in severe thrombocytopenia; and momelotinib has a differentiated role in anemia-dominant MF. Allogeneic hematopoietic cell transplantation remains the only curative strategy and should be discussed early for biologically or clinically high-risk disease. Emerging artificial intelligence (AI) applications in digital pathology, prognostic modeling, and post-transplant prediction may further operationalize precision care, but they remain adjunctive rather than autonomous and require external validation, explainability, governance, and human oversight before routine deployment. This review reframes MF through an MF-specific precision-medicine lens centered on biology, patient selection, phenotype-adapted treatment, transplantation, monitoring, and the boundary between what is currently actionable and what remains investigational.<\/jats:p>","DOI":"10.3389\/fonc.2026.1877425","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:11:50Z","timestamp":1784095910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision medicine in myelofibrosis: from molecular profiling to personalized therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Rafal","family":"Al-Shibly","sequence":"first","affiliation":[{"name":"Department of Medical Education, Internal Medicine Residency Program, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Kaddoura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","article-title":"International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms","volume":"482","author":"Gianelli","year":"2023","journal-title":"Virchows Arch"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283987","article-title":"Pathogenesis and management of high molecular risk myeloproliferative neoplasms","volume":"110","author":"Ling","year":"2025","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022415","article-title":"How I individualize selection of JAK inhibitors for patients with myelofibrosis","volume":"145","author":"Masarova","year":"2025","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019630","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408941","article-title":"Clearance of driver mutations after transplantation for myelofibrosis","volume":"392","author":"Gagelmann","year":"2025","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286123","article-title":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms","volume":"110","author":"Yu","year":"2025","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1881","article-title":"AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib","volume":"6","author":"Duminuco","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027287","article-title":"Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis","volume":"145","author":"Hern\u00e1ndez-Boluda","year":"2025","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bjh.19938","article-title":"Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology","volume":"206","author":"Wang","year":"2025","journal-title":"Br J Haematol"},{"key":"B27","article-title":"Marketing submission recommendations for a predetermined change control plan for artificial intelligence-enabled device software functions: guidance for industry and food and drug administration staff","year":"2025"},{"key":"B28","article-title":"AI Act. Shaping Europe\u2019s digital future","year":"2026"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10238-025-01830-9","article-title":"From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms","volume":"25","author":"Chen","year":"2025","journal-title":"Clin Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN Alliance study of 1095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1877425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:11:51Z","timestamp":1784095911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1877425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1877425"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1877425","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1877425"}}